Posts Tagged ‘GLP-1 agonists’

Progress Reported in MASH with Survodutide

February 27, 2024 — Yet another GLP-1 agonist in development for obesity – survodutide – showed promising results yesterday from a phase 2 clinical trial in MASH. In case you missed the notice, MASH is the new acronym for what we used to label as NASH. We also note that MASLD has replaced NAFLD in the nomenclature alphabet soup […]

“Weight Loss Jabs” Instead of Drug Rehab? Hold On, Folks

February 24, 2024 — This sounds like a godsend. “Weight loss jabs could be a more effective and cheaper treatment for drug addiction than rehab, a study suggests.” So says the Telegraph of London. The “weight loss jabs” they’re talking about are liraglutide 3 mg daily injections, also known by the brand name of Saxenda. Sad to say, they […]

Patent Thickets to Boost Obesity Medicine Prices

February 9, 2024 — Are patent thickets boosting the prices of obesity medicine prices and putting these important medical advances out of reach for everyone but the wealthy and well insured? A new paper in JAMA this week suggests this is true – at least in part. Rasha Alhiary and colleagues explain: “Manufacturers have secured long periods of market […]

More News Points to Explosive Growth for GLP-1 Medicines

February 7, 2024 — Let’s be clear from the start. Hype about “weight loss” drugs is exquisitely unhelpful. This is because weight loss is only an acute effect of new medicines that act on GLP-1 receptors and related pathways that influence obesity. The real need for these medicines is to control a whole range of chronic health problems that […]

Who Gets and Fills Prescriptions for Obesity Medicines?

January 31, 2024 — Obesity is the most prevalent chronic disease in America, so you might think that prescriptions for obesity medicines are relatively common – but only if you are unfamiliar with prevailing attitudes about these medicines. Because in fact, even in a large health system known for excellent care in cardiometabolic health, these prescriptions are rather rare. […]

Weight Regain in the Real World vs a Placebo-Controlled Trial

January 30, 2024 — It created quite a stir last week when Epic Research published an analysis suggesting that weight regain in the real world does not look the same as a placebo-controlled trial. After all, regain is quite an important subject. Obesity is clearly a chronic disease, requiring chronic care. But lots of people try to avoid this […]

Real World Data Say Not Everyone Regains All Their Weight

January 25, 2024 — One of the more annoying generalizations in obesity is the assertion that when people lose weight, everyone inevitably regains it all and perhaps even more. When said about metabolic surgery, it’s utterly false. But that doesn’t stop people from saying it – even people who pose as medical experts. More broadly in the medical management […]

Incentives for Metabolic Surgery in Response to GLP-1 Medicines

January 17, 2024 — Over the past year, as the world has embraced GLP-1 medicines like semaglutide for obesity, we have heard much speculation about dire prospects for the future of metabolic surgery. Stock prices dropped earlier this year for medical device companies with big investments in bariatric surgery when Intuitive Surgical announced they were seeing a slowdown in […]

Lancet: Obesity Drugs Won’t Save Us from Cheeseburgers

January 10, 2024 — Some things never change. Half a century ago, editors of the Lancet proclaimed that “most obesity could, with care, be prevented.” Drugs have “limited usefulness” for treating obesity, they explained, and so, “we need to be more vigilant about preventing obesity throughout childhood.” After 50 years of relying on this advice, obesity prevalence has tripled. […]

Will GLP-1 Medicines Widen the Economic Rift in Health?

January 8, 2024 — Right now, the promise of GLP-1 medicines for obesity, though revolutionary, is serving only to widen the economic rift in health. People with extraordinary wealth or generous health insurance plans receive the health benefits that flow from treating obesity effectively – which include a longer life, fewer strokes, and fewer heart attacks. Others are consigned […]